Hsbc Holdings PLC Geron Corp Transaction History

Hsbc Holdings PLC

$160 Billion
Q2 2024

A detailed history of Hsbc Holdings PLC transactions in Geron Corp stock. As of the latest transaction made, Hsbc Holdings PLC holds 69,405 shares of GERN stock, worth $307,464. This represents 0.0% of its overall portfolio holdings.

Number of Shares

69,405

Previous 53,576 29.54%

Holding current value

$307,464

Previous $176,000 67.05%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$3.1 - $5.09 $49,069 - $80,569	15,829 Added 29.54%	69,405 $294,000
Q1 2024 May 15, 2024	BUY	$1.75 - $3.44 $93,758 - $184,301	53,576 New	53,576 $176,000
Q3 2021 Nov 12, 2021	SELL	$1.2 - $1.5 $13,792 - $17,241	-11,494 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$1.25 - $1.83 $14,367 - $21,034	11,494 New	11,494 $16,000
Q1 2021 May 14, 2021	SELL	$1.52 - $2.1 $42,935 - $59,318	-28,247 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$1.55 - $2.05 $43,782 - $57,906	28,247 New	28,247 $44,000
Q3 2020 Nov 12, 2020	SELL	$1.59 - $2.19 $33,549 - $46,209	-21,100 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.05 - $2.18 $6,982 - $14,497	6,650 Added 46.02%	21,100 $46,000
Q1 2020 May 15, 2020	SELL	$0.89 - $1.49 $6,436 - $10,775	-7,232 Reduced 33.35%	14,450 $17,000
Q4 2019 Feb 14, 2020	BUY	$1.27 - $1.54 $2,926 - $3,548	2,304 Added 11.89%	21,682 $30,000
Q3 2019 Nov 14, 2019	BUY	$1.15 - $1.59 $9,267 - $12,813	8,059 Added 71.2%	19,378 $26,000
Q2 2019 Aug 13, 2019	SELL	$1.37 - $2.02 $2,622 - $3,866	-1,914 Reduced 14.46%	11,319 $16,000
Q1 2019 May 15, 2019	BUY	$1.01 - $1.83 $13,365 - $24,216	13,233 New	13,233 $22,000

Others Institutions Holding GERN

# of Institutions

258

Shares Held

448M

Call Options Held

1.91M

Put Options Held

897K

View Full List

About GERON CORP

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.67B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

More about GERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.

Account

Hsbc Holdings PLC Geron Corp Transaction History